Article
Progress and challenges for treating Type 1 diabetes.
Journal of autoimmunity - 1 Jul 2016
Garyu Justin W, Meffre Eric, Cotsapas Chris, Herold Kevan C
Abstract excerpt
It has been more than 30 years since the initial trials of Cyclosporin A to treat patients with new onset Type 1 diabetes (T1D). Since that time, there have been insights into genetic predisposition to the disease, the failures of immune tolerance, and mechanisms that cause the immune mediated β cell destruction. The genetic loci associated affect lymphocyte development and tolerance mechanisms. Discoveries...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
